Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial

To evaluate the effects of separate and combined use of the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor dapagliflozin and the glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) exenatide on measures of kidney function.

[1]  Shusen Sun,et al.  Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury. , 2020, Clinical journal of the American Society of Nephrology : CJASN.

[2]  F. Giorgino,et al.  Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis , 2019, Scientific Reports.

[3]  R. Holman,et al.  Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial , 2019, Cardiovascular Diabetology.

[4]  J. McMurray,et al.  Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. , 2019, The lancet. Diabetes & endocrinology.

[5]  D. Wheeler,et al.  Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. , 2019, The lancet. Diabetes & endocrinology.

[6]  B. Zinman,et al.  Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. , 2019, The lancet. Diabetes & endocrinology.

[7]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[8]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[9]  A. Saremi,et al.  Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. , 2018, The lancet. Diabetes & endocrinology.

[10]  K. Mahaffey,et al.  Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. , 2018, The lancet. Diabetes & endocrinology.

[11]  K. Tuttle,et al.  Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. , 2018, The lancet. Diabetes & endocrinology.

[12]  R. IJzerman,et al.  SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management , 2018, Diabetes Care.

[13]  B. Ludvik,et al.  Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. , 2018, The lancet. Diabetes & endocrinology.

[14]  G. Laverman,et al.  The albuminuria‐lowering response to dapagliflozin is variable and reproducible among individual patients , 2017, Diabetes, obesity and metabolism.

[15]  E. Hoorn,et al.  GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes , 2017, Nature Reviews Nephrology.

[16]  B. Zinman,et al.  Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. , 2017, The lancet. Diabetes & endocrinology.

[17]  J. Eriksson,et al.  Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year , 2017, Diabetes, obesity & metabolism.

[18]  É. Hardy,et al.  Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. , 2016, The lancet. Diabetes & endocrinology.

[19]  M. Lanaspa,et al.  Acute kidney injury from SGLT2 inhibitors: potential mechanisms , 2016, Nature Reviews Nephrology.

[20]  D. Fitchett,et al.  Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.

[21]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[22]  H. Heerspink,et al.  Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers , 2016, Diabetes, obesity & metabolism.

[23]  A. Levey,et al.  Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. , 2015, JAMA.

[24]  D. de Zeeuw,et al.  Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes , 2013, Diabetes, obesity & metabolism.

[25]  Harold I Feldman,et al.  Estimating glomerular filtration rate from serum creatinine and cystatin C. , 2012, The New England journal of medicine.

[26]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.